Illinois Municipal Retirement Fund Has $3.70 Million Position in Glaukos Corporation $GKOS

Posted by Francis Steltz on Jul 19th, 2026

Illinois Municipal Retirement Fund raised its position in Glaukos Corporation (NYSE:GKOS – Free Report) by 13.3% in the 1st quarter, Holdings Channel reports. The firm owned 34,395 shares of the medical instruments supplier’s stock after buying an additional 4,025 shares during the period. Illinois Municipal Retirement Fund’s holdings in Glaukos were worth $3,703,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of GKOS. First Horizon Corp boosted its position in shares of Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Glaukos in the 4th quarter valued at $28,000. Larson Financial Group LLC increased its position in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 215 shares in the last quarter. Finally, Salomon & Ludwin LLC raised its stake in Glaukos by 111.2% during the 4th quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 239 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on GKOS shares. Citigroup lifted their target price on Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Wells Fargo & Company increased their price target on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. raised their price target on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. HC Wainwright assumed coverage on Glaukos in a report on Monday, July 6th. They set a “buy” rating and a $168.00 price objective on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $154.85.

View Our Latest Research Report on GKOS

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. The trade was a 7.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the sale, the chief operating officer directly owned 73,419 shares in the company, valued at $10,538,563.26. This trade represents a 21.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 61,273 shares of company stock valued at $8,882,003. 5.90% of the stock is currently owned by company insiders.

Glaukos Trading Up 1.0%

GKOS opened at $156.97 on Friday. The stock has a market capitalization of $9.22 billion, a P/E ratio of -47.86 and a beta of 0.75. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $161.53. The firm’s fifty day simple moving average is $134.39 and its 200 day simple moving average is $122.04. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) EPS. As a group, research analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Glaukos Company Profile

(Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.